RxDoctor Payments Data

Alexis Baird, PA

Physician Assistant · Anchorage, AKNPI 1679970131

Payments from drug & device makers

$799in general payments, 2019–2025

Across 25 payments — averaging $31.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$129
  • AstraZeneca$128
  • Medtronic$114
  • Corcept Therapeutics$100
  • Novo Nordisk$87
  • Amgen$77
  • plus $165 from 6 others

What the payments were for

  • Food & beverage$75594%
  • Education$446%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$799 in reported general payments places this provider in the 80th percentile of 365 physician assistant providers in Alaska.

See all physician assistant providers in Alaska

Medicare billing

Part B allowed, 2024
$50,862
Medicare patients
101
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide147$186,985
OzempicSemaglutide90$149,833
TrulicityDulaglutide35$53,115
FarxigaDapagliflozin Propanediol29$36,726
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/742$35,541
JardianceEmpagliflozin21$32,065
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt17$31,661
Humalog Kwikpen U-200Insulin Lispro12$27,160
Tresiba Flextouch U-200Insulin Degludec16$21,168
GlyxambiEmpagliflozin/Linagliptin12$18,509
JanuviaSitagliptin Phosphate19$14,790
Fiasp FlextouchInsulin Aspart (Niacinamide)18$13,089
Tresiba Flextouch U-100Insulin Degludec14$11,025
HumalogInsulin Lispro42$10,122
Humalog Kwikpen U-100Insulin Lispro27$9,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$12$250,222224 claims
Novo NordiskOzempic$87$149,83390 claims
AstraZenecaFarxiga$128$36,72629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 physician assistant providers in Alaska.

Other physician assistant in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →